Guidelines for health economics research are being developed around the world by academic groups, government organizations, and consultants. As reviewed in this paper, there are many similarities that will enable some comparison of studies across countries. There are also important differences in the guidelines that may prevent comparability across studies. As guidelines are being developed, there needs to be a coordinated effort among the various developers to ensure that guidelines are applicable in various settings, that the science is not stifled, and that guidelines provide benefit to those ultimately impacted, the patients.
DrummondM. Guidelines for Pharmacoeconomic Studies—The Ways Forward. PharmacoEcon.1994; 6(6):493–497.
2.
Commonwealth Department of Health, Housing and Community Services.Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee—including submissions involving economic analyses. Canberra: Australian Government Publishing Service; August 1992.
3.
Canadian Coordinating Office for Health Technology Assessment.Guidelines for Economic Evaluation of Pharmaceutical: Canada. 1st ed.Ottawa: CCOHTA; 1994.
4.
Ministry of Health.Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Fall 1994.
5.
The Harmonisation by Consensus of the Methodology for Economic Evaluation of Health Technologies in the European Union—a concentrated action of the European Union's Biomedical and Health Research Programme. Newsletter 1, November 1994.
6.
GarattiniLGrilliRScopellitiDMantovaniL. A Proposal For Italian Guidelines in Pharmacoeconomics. PharmacoEcon.1995;7(1):1–6.
7.
General Directorate of Services and Evaluation of Health Technologies and the General Directorate of Insurance and Health Planning of the Ministry of Health and Consumption. Proposal for Standardisation of Some Methodological Aspects of Cost-Effectiveness Analyses (CEA), Cost-Utility Analyses (CUA), and Cost-Minimization Analyses (CMA) in the Evaluation of Health Technologies and Programmes. Spain; February 1994.
8.
Swiss Federal Office of Social Security.Manual for the Standardisation of Clinical and Economic Evaluation of Medical Technology. Second Draft. Switzerland; April 4, 1995.
9.
Series on Health Economics, Discussion Publication No. 10. Guidelines for the Economic Evaluation of Health Commodities and Services. University of Hannover, Department of Economic Sciences and North German Centre for Health Services Research; Germany; January 1995.
10.
Document final adopte par la Commission de Transparence du 12 juin 1995. Acceptabilite des etudes Medico-Economique, en terme de contenu et de presentation. France; 1995.
11.
ABPI-Government Strategic Working Group.Guidance on Good Practice in the Conduct of Economic Evaluations of Medicines. United Kingdom; May 1994.
12.
BuxtonM. International Perspective on Guidelines Development: Approaches, Challenges, and Future Directions the United Kingdom. Proceedings from the Canadian Collaborative Workshop on Pharmacoeconomics, Quebec, June 21-22, 1993.
13.
Task Force on Principles for Economic Analysis of Health Care Technology.Economic Analysis of Health Care Technology, A Report on Principles. Ann Intern Med.1995;122:61–70.
14.
PhRMA Task Force on the Economic Evaluation of Pharmaceuticals.Methodological and Conduct Principles for Pharmacoeconomic Research. Washington, DC: Pharmaceutical Research and Manufacturers of America; January 1995.
15.
A Practical Guide to Prevention Effectiveness: Decision and Economic Analysis. Atlanta, GA: US Department of Health and Human Services, US Public Health Services, Center for Disease Control and Prevention (CDC).
16.
Conference Sponsored by the US Food and Drug Administration.Comparing Treatments: Safety, Effectiveness and Cost-Effectiveness. March 23-24, 1995, Masur Auditorium, National Institute of Health, Bethesda, Maryland.
17.
GoldMSiegelJRussellLWeinsteinM, eds. Cost-Effectiveness in Health and Medicine.New York: Oxford University Press; 1996.
18.
DrummondMBrandtALuceBRoviraJ. Standardizing Methodologies for Economic Evaluation in Health Care-Practice, Problems and Potential. Int J Tech Assess Health Care.1993;9(1):26–36.
19.
KassierJAngellM. The Journal's Policy on Cost-Effectiveness Analyses. New Eng J Med.1994; 331(10):669–670.
20.
KassierJAngellM. Correspondence. New Eng J Med.1995:332:123–125.
21.
A Dictionary of Epidemiology.Second Edition. LastJohn (ed) New York: Oxford University Press; 1988, p. 41.
22.
SimonGWagnerEVonkorffM. Cost-Effective Comparisons Using “Real World” Randomized Trials: The Case of New Antidepressants Drugs. J Clin Epidemiology.1995;48(3):363–373.
23.
MullinsC. Combing the Principles of Epidemiology and Economics. Am J Pharma Education.1994; 58:427–430.
